MétaCan
Menu
Back to cohort

Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).

2016· article· en· W2752996975 on OpenAlexaff
Eric J. Small, Rahul Aggarwal, Jiaoti Huang, Artem Sokolov, Li Zhang, Joshi J. Alumkal, Jack Youngren, Charles J. Ryan, Adam Foye, Robert E. Reiter, Christopher P. Evans, Martin Gleave, Owen N. Witte, Joshua M. Stuart, Theodore C. Goldstein, George Thomas, Lawrence D. True, Himisha Beltran, Mark A. Rubin, Tomasz M. Beer

Bibliographic record

VenueJournal of Clinical Oncology · 2016
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsUniversity of British Columbia
Fundersnot available
KeywordsMedicineProstate cancerBiopsyEnzalutamideProstateCancerPathologyOncologyInternal medicineAndrogen receptor

Abstract

fetched live from OpenAlex

5019 Background: SCNC and a novel pathologic subtype, IAC, comprise a growing proportion of mCRPC patients resistant to androgen signaling inhibitors such as Abiraterone (Abi) or Enzalutamide (Enz). We sought to characterize these non-adenocarcinoma (adeno) subtypes in a prospective biopsy study. Methods: Eligible mCRPC pts underwent a metastasis biopsy (bx), and were followed for clinical outcomes. Tissue was both frozen and formalin fixed/paraffin embedded (FFPE). Independent review of FFPE specimens was undertaken by 3 pathologists. Frozen specimens underwent laser capture micro-dissection prior to RNA sequencing (seq). Machine learning was used to derive histology-specific expression signatures. Signature accuracy was evaluated with leave-pair-out cross-validation and application to an independent data set. Results: 226 of 300 planned mCRPC pts (74% resistant to Abi and/or Enz) have undergone bx (including 123 bone, 61 node, and 23 liver bx) with a 78% evaluable biopsy rate. Adeno was identified in 39%, non-adeno in 41% (SCNC in 12%, IAC in 29%), with other mixtures in the remaining 20%. Median overall survival (OS) from time of biopsy for pts with non-adeno histologies was 12.8 months (mos) [ IAC OS = 19.1 mos; SCNC OS = 12.8 mos] versus 25.8 mos in adeno pts (p=0.023). RNAseq data are available from 94 bx. Transcriptional signatures were developed which accurately distinguish adeno, SCNC and IAC. IAC appears to have a signature intermediate between adeno and SCNC. When applied to an independent data set (Beltran et al, Ca Disc 2011), these transcriptional signatures identified SCNC with 100% accuracy, and predict for IAC differentiation in a subset of non-SCNC tumors. Conclusions: A majority of CRPC metastases exhibit non-adenocarcinoma features, which are associated with a shortened survival. IAC and SCNC are genomically distinct, and newly derived transcriptional signatures based on these bx can be used to identify SCNC in an independent data set. Integration of whole exome with RNA-seq data are ongoing to identify pathways up-regulated in IAC and SCNC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.089
GPT teacher head0.433
Teacher spread0.344 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations15
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicProstate Cancer Treatment and ResearchFrench-language works237,207